# Sto-Rahoitus

> Sto-Rahoitus is a VC fund in Helsinki backing Biotechnology, Medical and Software. See 2 investments, check sizes, portfolio. Updated Sep 2026.

- Type: VC Fund
- Location: Helsinki, Finland
- Total investments: 2
- Last investment: Dec 2017
- Lead investor: 0%
- Last updated: Sep 2026

Sto-Rahoitus is a VC fund in Helsinki focused on Biotechnology and Medical. Sto-Rahoitus

## Round sizes

| Stage | Round size |
| --- | --- |
| Series A | $2M–$5.9M |

## Investment focus

### Industry

| Industry | Investments | Share |
| --- | --- | --- |
| Biotechnology | 2 | 100% |
| Medical | 1 | 50% |
| Software | 1 | 50% |
| Education | 1 | 50% |
| Health Care | 1 | 50% |

11 industries tracked in total.

## Investments

| Company | Description | Amount | Stage | Date | Website |
| --- | --- | --- | --- | --- | --- |
| Aiforia | Aiforia Technologies was founded as a spin-off company from the Finnish Institute for Molecular Medicine (FIMM) at the University of Helsinki in 2013 by researchers and pioneers in the field of cloud-based microscopy and pathology and experienced life science entrepreneurs. The Aiforia® Platform brings together deep learning AI and high-performancecloud computing. Aiforia assists with the increased demand for image-based diagnostics by providing efficient and scalable solutions – enabling new discoveries and clinical support with highly accurate and consistent data. Aiforia is technologically driven establishment and keeps the capability of being image agnostic thus extending its solutions to multiple fields. | $5.9M | Series A | Dec 01, 2017 |  |
| Desentum | Desentum is a research-oriented biopharmaceutical company specialized in developing novel types of allergy vaccines that are based on switching the immune system's response to allergens from hypersensitivity to tolerance. They have a unique approach for designing allergy vaccines. By studying the molecular mechanism of the hypersensitivityreaction, they have made discoveries that allow for improved design of vaccines against common types of allergies. Their goal is to provide long-term relief for patients suffering from allergic symptoms, as well as reduce the social and economic burden allergies cause to both individuals and society. | $2M | Series A | Jan 23, 2017 |  |

2 of 2 investments shown.

## Co-investors
- [ACME Investments](https://shizune.co/investors/profile/acme-investments) — VC Fund, 1 deal together
- [Ascend Capital Partners](https://shizune.co/investors/profile/ascend-capital-partners-6051) — VC Fund, 1 deal together
- [Cascara Ventures](https://shizune.co/investors/profile/cascara-ventures) — VC Fund, 1 deal together
- [Luxembourgian ACME Investments](https://shizune.co/investors/profile/luxembourgian-acme-investments) — VC Fund, 1 deal together
- [VTT Ventures](https://shizune.co/investors/profile/vtt-ventures) — VC Fund, 1 deal together

## Similar investors

### Similar industry
- [SOSV](https://shizune.co/investors/profile/sosv) — VC Fund
- [ARCH Venture Partners](https://shizune.co/investors/profile/arch-venture-partners) — VC Fund
- [OrbiMed](https://shizune.co/investors/profile/orbimed-advisors) — VC Fund

### Similar stage
- [Antler](https://shizune.co/investors/profile/antler-be9c) — VC Fund
- [Alumni Ventures](https://shizune.co/investors/profile/alumni-ventures-group) — VC Fund
- [FJ Labs](https://shizune.co/investors/profile/fj-labs) — VC Fund

### Similar country
- [Business Finland](https://shizune.co/investors/profile/tekes) — VC Fund
- [Lifeline Ventures](https://shizune.co/investors/profile/lifeline-ventures) — VC Fund
- [Tesi](https://shizune.co/investors/profile/tesi) — VC Fund

## Featured in investor lists
- [Biotechnology Investors in Finland](https://shizune.co/investors/biotechnology-investors-finland)
- [Biotechnology VC Funds in Finland](https://shizune.co/investors/biotechnology-vc-funds-finland)
- [Biotech VC Funds in Finland](https://shizune.co/investors/biotech-vc-funds-finland)
- [Education VC Funds in Finland](https://shizune.co/investors/education-vc-funds-finland)
- [EdTech VC Funds in Finland](https://shizune.co/investors/edtech-vc-funds-finland)

## FAQ

### What does Sto-Rahoitus invest in?

Sto-Rahoitus invests primarily in Biotechnology, Medical and Software startups, most often at Series A stage. Most of the 2 investments tracked by Shizune back companies in Finland. The Investment Focus section breaks down every industry, stage and country in the portfolio.

### What is Sto-Rahoitus's check size?

Sto-Rahoitus typically joins rounds of $2M–$5.9M at Series A. These ranges are 10th–90th percentile round sizes calculated from confirmed public funding rounds, so they are a realistic guide to the rounds Sto-Rahoitus participates in.

### When did Sto-Rahoitus last invest?

The most recent investment recorded for Sto-Rahoitus closed in Dec 2017. Shizune tracks 2 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.

### Is Shizune's investor data accurate?

Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Sep 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.

# About Shizune
Shizune.co is an investor database. Core features:
- 48,091 startup investors (angels, VCs, accelerators, and others)
- Email, phone, LinkedIn (for intros), socials, and other contact data
- Updated daily from public funding news
- CSV and Excel export

The User can access the full database FOR FREE after signing up: shizune.co